EBITDA: Income before interest, taxes, depreciation and amortization.
Cogent Biosciences, Inc. (COGT) had EBITDA of $-74.65M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-73.53M |
|
-- |
|
-- |
|
$75.58M |
|
$-75.58M |
|
$2.05M |
|
$-73.53M |
|
$-73.53M |
|
$-73.53M |
|
$-73.53M |
|
$-73.53M |
|
$-73.53M |
|
$-75.58M |
|
|
EBITDA |
$-74.65M |
114.47M |
|
114.47M |
|
$-0.53 |
|
$-0.53 |
|
| Balance Sheet Financials | |
$245.01M |
|
$5.85M |
|
$29.81M |
|
$274.82M |
|
$58.42M |
|
-- |
|
$61.36M |
|
$119.78M |
|
$47.12M |
|
$155.04M |
|
$155.04M |
|
113.93M |
|
| Cash Flow Statement Financials | |
$-121.05M |
|
$78.29M |
|
$72.20M |
|
$98.17M |
|
$127.60M |
|
$29.43M |
|
$19.72M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.19 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-121.73M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-156.04% |
|
-47.43% |
|
-26.76% |
|
-47.43% |
|
$1.36 |
|
$-1.06 |
|
$-1.06 |
|